人工呼吸器関連肺炎（VAP）治療薬の世界市場（～2026年）

• 英文タイトル：Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY05003 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、133ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は人工呼吸器関連肺炎（VAP）治療薬のグローバル市場について調査・分析したレポートです。種類別（予防、理学療法、免疫療法）市場規模、用途別（病院、外来外科センター、診断センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別人工呼吸器関連肺炎（VAP）治療薬の競争状況、市場シェア ・世界の人工呼吸器関連肺炎（VAP）治療薬市場：種類別市場規模 2015年-2020年（予防、理学療法、免疫療法） ・世界の人工呼吸器関連肺炎（VAP）治療薬市場：種類別市場規模予測 2021年-2026年（予防、理学療法、免疫療法） ・世界の人工呼吸器関連肺炎（VAP）治療薬市場：用途別市場規模 2015年-2020年（病院、外来外科センター、診断センター） ・世界の人工呼吸器関連肺炎（VAP）治療薬市場：用途別市場規模予測 2021年-2026年（病院、外来外科センター、診断センター） ・北米の人工呼吸器関連肺炎（VAP）治療薬市場分析：米国、カナダ ・ヨーロッパの人工呼吸器関連肺炎（VAP）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの人工呼吸器関連肺炎（VAP）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の人工呼吸器関連肺炎（VAP）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの人工呼吸器関連肺炎（VAP）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Achaogen Inc、Adenium Biotech ApS、Aridis Pharmaceuticals LLC、AstraZeneca Plc、Bayer AG、Cardeas Pharma Corp、Destiny Pharma Ltd、Dong-A Socio Holdings Co Ltd、Lakewood-Amedex Inc、MedImmune LLC、Meiji Seika Pharma Co Ltd、Merck & Co Inc、Motif Bio Plc、Nabriva Therapeutics AG、Polyphor Ltd、Shionogi & Co Ltd、Tetraphase Pharmaceuticals Inc、The Medicines Company、Theravance Biopharma Inc、Wockhardt Ltd、Zavante Therapeutics Inc ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global Ventilator Associated Pneumonia (VAP) Therapeutics Market
The global Ventilator Associated Pneumonia (VAP) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Ventilator Associated Pneumonia (VAP) Therapeutics Scope and Market Size
Ventilator Associated Pneumonia (VAP) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Ventilator Associated Pneumonia (VAP) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Achaogen Inc
Adenium Biotech ApS
Aridis Pharmaceuticals LLC
AstraZeneca Plc
Bayer AG
Cardeas Pharma Corp
Destiny Pharma Ltd
Dong-A Socio Holdings Co Ltd
Lakewood-Amedex Inc
MedImmune LLC
Meiji Seika Pharma Co Ltd
Merck & Co Inc
Motif Bio Plc
Nabriva Therapeutics AG
Polyphor Ltd
Shionogi & Co Ltd
Tetraphase Pharmaceuticals Inc
The Medicines Company
Theravance Biopharma Inc
Wockhardt Ltd
Zavante Therapeutics Inc

Market segment by Type, the product can be split into
Prevention
Physiotherapy
Immunity Therapy
Market segment by Application, split into
Hospitals
Ambulatory Surgical Center
Diagnostic Centers

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Prevention
1.4.3 Physiotherapy
1.4.4 Immunity Therapy
1.5 Market by Application
1.5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Center
1.5.4 Diagnostic Centers
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Perspective (2015-2026)
2.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Growth Trends by Regions
2.2.1 Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Ventilator Associated Pneumonia (VAP) Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Ventilator Associated Pneumonia (VAP) Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Market Size
3.1.1 Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio
3.2.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2019
3.3 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players Head office and Area Served
3.4 Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
3.5 Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)
5.2 Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
6.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in North America (2019-2020)
6.3 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
6.4 North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
7.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
7.4 Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
8.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in China (2019-2020)
8.3 China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
8.4 China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
9.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
9.4 Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
10.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
11.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in India (2019-2020)
11.3 India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
11.4 India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size (2015-2020)
12.2 Ventilator Associated Pneumonia (VAP) Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Achaogen Inc
13.1.1 Achaogen Inc Company Details
13.1.2 Achaogen Inc Business Overview
13.1.3 Achaogen Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
13.1.4 Achaogen Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020))
13.1.5 Achaogen Inc Recent Development
13.2 Adenium Biotech ApS
13.2.1 Adenium Biotech ApS Company Details
13.2.2 Adenium Biotech ApS Business Overview
13.2.3 Adenium Biotech ApS Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
13.2.4 Adenium Biotech ApS Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
13.2.5 Adenium Biotech ApS Recent Development
13.3 Aridis Pharmaceuticals LLC
13.3.1 Aridis Pharmaceuticals LLC Company Details
13.3.2 Aridis Pharmaceuticals LLC Business Overview
13.3.3 Aridis Pharmaceuticals LLC Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
13.3.4 Aridis Pharmaceuticals LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
13.3.5 Aridis Pharmaceuticals LLC Recent Development
13.4 AstraZeneca Plc
13.4.1 AstraZeneca Plc Company Details
13.4.2 AstraZeneca Plc Business Overview
13.4.3 AstraZeneca Plc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
13.4.4 AstraZeneca Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
13.4.5 AstraZeneca Plc Recent Development
13.5 Bayer AG
13.5.1 Bayer AG Company Details
13.5.2 Bayer AG Business Overview
13.5.3 Bayer AG Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
13.5.4 Bayer AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
13.5.5 Bayer AG Recent Development
13.6 Cardeas Pharma Corp
13.6.1 Cardeas Pharma Corp Company Details
13.6.2 Cardeas Pharma Corp Business Overview
13.6.3 Cardeas Pharma Corp Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
13.6.4 Cardeas Pharma Corp Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
13.6.5 Cardeas Pharma Corp Recent Development
13.7 Destiny Pharma Ltd
13.7.1 Destiny Pharma Ltd Company Details
13.7.2 Destiny Pharma Ltd Business Overview
13.7.3 Destiny Pharma Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
13.7.4 Destiny Pharma Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
13.7.5 Destiny Pharma Ltd Recent Development
13.8 Dong-A Socio Holdings Co Ltd
13.8.1 Dong-A Socio Holdings Co Ltd Company Details
13.8.2 Dong-A Socio Holdings Co Ltd Business Overview
13.8.3 Dong-A Socio Holdings Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
13.8.4 Dong-A Socio Holdings Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
13.8.5 Dong-A Socio Holdings Co Ltd Recent Development
13.9 Lakewood-Amedex Inc
13.9.1 Lakewood-Amedex Inc Company Details
13.9.2 Lakewood-Amedex Inc Business Overview
13.9.3 Lakewood-Amedex Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
13.9.4 Lakewood-Amedex Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
13.9.5 Lakewood-Amedex Inc Recent Development
13.10 MedImmune LLC
13.10.1 MedImmune LLC Company Details
13.10.2 MedImmune LLC Business Overview
13.10.3 MedImmune LLC Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
13.10.4 MedImmune LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
13.10.5 MedImmune LLC Recent Development
13.11 Meiji Seika Pharma Co Ltd
10.11.1 Meiji Seika Pharma Co Ltd Company Details
10.11.2 Meiji Seika Pharma Co Ltd Business Overview
10.11.3 Meiji Seika Pharma Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.11.4 Meiji Seika Pharma Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.11.5 Meiji Seika Pharma Co Ltd Recent Development
13.12 Merck & Co Inc
10.12.1 Merck & Co Inc Company Details
10.12.2 Merck & Co Inc Business Overview
10.12.3 Merck & Co Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.12.4 Merck & Co Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.12.5 Merck & Co Inc Recent Development
13.13 Motif Bio Plc
10.13.1 Motif Bio Plc Company Details
10.13.2 Motif Bio Plc Business Overview
10.13.3 Motif Bio Plc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.13.4 Motif Bio Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.13.5 Motif Bio Plc Recent Development
13.14 Nabriva Therapeutics AG
10.14.1 Nabriva Therapeutics AG Company Details
10.14.2 Nabriva Therapeutics AG Business Overview
10.14.3 Nabriva Therapeutics AG Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.14.4 Nabriva Therapeutics AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.14.5 Nabriva Therapeutics AG Recent Development
13.15 Polyphor Ltd
10.15.1 Polyphor Ltd Company Details
10.15.2 Polyphor Ltd Business Overview
10.15.3 Polyphor Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.15.4 Polyphor Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.15.5 Polyphor Ltd Recent Development
13.16 Shionogi & Co Ltd
10.16.1 Shionogi & Co Ltd Company Details
10.16.2 Shionogi & Co Ltd Business Overview
10.16.3 Shionogi & Co Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.16.4 Shionogi & Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.16.5 Shionogi & Co Ltd Recent Development
13.17 Tetraphase Pharmaceuticals Inc
10.17.1 Tetraphase Pharmaceuticals Inc Company Details
10.17.2 Tetraphase Pharmaceuticals Inc Business Overview
10.17.3 Tetraphase Pharmaceuticals Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.17.4 Tetraphase Pharmaceuticals Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.17.5 Tetraphase Pharmaceuticals Inc Recent Development
13.18 The Medicines Company
10.18.1 The Medicines Company Company Details
10.18.2 The Medicines Company Business Overview
10.18.3 The Medicines Company Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.18.4 The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.18.5 The Medicines Company Recent Development
13.19 Theravance Biopharma Inc
10.19.1 Theravance Biopharma Inc Company Details
10.19.2 Theravance Biopharma Inc Business Overview
10.19.3 Theravance Biopharma Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.19.4 Theravance Biopharma Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.19.5 Theravance Biopharma Inc Recent Development
13.20 Wockhardt Ltd
10.20.1 Wockhardt Ltd Company Details
10.20.2 Wockhardt Ltd Business Overview
10.20.3 Wockhardt Ltd Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.20.4 Wockhardt Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.20.5 Wockhardt Ltd Recent Development
13.21 Zavante Therapeutics Inc
10.21.1 Zavante Therapeutics Inc Company Details
10.21.2 Zavante Therapeutics Inc Business Overview
10.21.3 Zavante Therapeutics Inc Ventilator Associated Pneumonia (VAP) Therapeutics Introduction
10.21.4 Zavante Therapeutics Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020)
10.21.5 Zavante Therapeutics Inc Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Ventilator Associated Pneumonia (VAP) Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue
Table 3. Ranking of Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Prevention
Table 6. Key Players of Physiotherapy
Table 7. Key Players of Immunity Therapy
Table 8. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Ventilator Associated Pneumonia (VAP) Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Ventilator Associated Pneumonia (VAP) Therapeutics Market Growth Strategy
Table 18. Main Points Interviewed from Key Ventilator Associated Pneumonia (VAP) Therapeutics Players
Table 19. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 20. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players (2015-2020)
Table 21. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2019)
Table 22. Global Ventilator Associated Pneumonia (VAP) Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Product Solution and Service
Table 25. Date of Enter into Ventilator Associated Pneumonia (VAP) Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 28. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Type (2015-2020)
Table 29. Global Ventilator Associated Pneumonia (VAP) Therapeutics Revenue Market Share by Type (2021-2026)
Table 30. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Application (2015-2020)
Table 31. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 32. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size Share by Application (2021-2026)
Table 33. North America Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Market Share (2019-2020)
Table 35. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 36. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2015-2020)
Table 37. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 38. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2015-2020)
Table 39. Europe Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Market Share (2019-2020)
Table 41. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2015-2020)
Table 43. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2015-2020)
Table 45. China Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (2019-2020) (Million US$)
Table 46. China Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Market Share (2019-2020)
Table 47. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 48. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2015-2020)
Table 49. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 50. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2015-2020)
Table 51. Japan Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Market Share (2019-2020)
Table 53. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2015-2020)
Table 55. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Market Share (2019-2020)
Table 59. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2015-2020)
Table 61. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2015-2020)
Table 63. India Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (2019-2020) (Million US$)
Table 64. India Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Market Share (2019-2020)
Table 65. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 66. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2015-2020)
Table 67. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 68. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Ventilator Associated Pneumonia (VAP) Therapeutics Market Share (2019-2020)
Table 71. Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type (2015-2020)
Table 73. Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application (2015-2020)
Table 75. Achaogen Inc Company Details
Table 76. Achaogen Inc Business Overview
Table 77. Achaogen Inc Product
Table 78. Achaogen Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 79. Achaogen Inc Recent Development
Table 80. Adenium Biotech ApS Company Details
Table 81. Adenium Biotech ApS Business Overview
Table 82. Adenium Biotech ApS Product
Table 83. Adenium Biotech ApS Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 84. Adenium Biotech ApS Recent Development
Table 85. Aridis Pharmaceuticals LLC Company Details
Table 86. Aridis Pharmaceuticals LLC Business Overview
Table 87. Aridis Pharmaceuticals LLC Product
Table 88. Aridis Pharmaceuticals LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 89. Aridis Pharmaceuticals LLC Recent Development
Table 90. AstraZeneca Plc Company Details
Table 91. AstraZeneca Plc Business Overview
Table 92. AstraZeneca Plc Product
Table 93. AstraZeneca Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 94. AstraZeneca Plc Recent Development
Table 95. Bayer AG Company Details
Table 96. Bayer AG Business Overview
Table 97. Bayer AG Product
Table 98. Bayer AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 99. Bayer AG Recent Development
Table 100. Cardeas Pharma Corp Company Details
Table 101. Cardeas Pharma Corp Business Overview
Table 102. Cardeas Pharma Corp Product
Table 103. Cardeas Pharma Corp Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 104. Cardeas Pharma Corp Recent Development
Table 105. Destiny Pharma Ltd Company Details
Table 106. Destiny Pharma Ltd Business Overview
Table 107. Destiny Pharma Ltd Product
Table 108. Destiny Pharma Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 109. Destiny Pharma Ltd Recent Development
Table 110. Dong-A Socio Holdings Co Ltd Business Overview
Table 111. Dong-A Socio Holdings Co Ltd Product
Table 112. Dong-A Socio Holdings Co Ltd Company Details
Table 113. Dong-A Socio Holdings Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 114. Dong-A Socio Holdings Co Ltd Recent Development
Table 115. Lakewood-Amedex Inc Company Details
Table 116. Lakewood-Amedex Inc Business Overview
Table 117. Lakewood-Amedex Inc Product
Table 118. Lakewood-Amedex Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 119. Lakewood-Amedex Inc Recent Development
Table 120. MedImmune LLC Company Details
Table 121. MedImmune LLC Business Overview
Table 122. MedImmune LLC Product
Table 123. MedImmune LLC Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 124. MedImmune LLC Recent Development
Table 125. Meiji Seika Pharma Co Ltd Company Details
Table 126. Meiji Seika Pharma Co Ltd Business Overview
Table 127. Meiji Seika Pharma Co Ltd Product
Table 128. Meiji Seika Pharma Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 129. Meiji Seika Pharma Co Ltd Recent Development
Table 130. Merck & Co Inc Company Details
Table 131. Merck & Co Inc Business Overview
Table 132. Merck & Co Inc Product
Table 133. Merck & Co Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 134. Merck & Co Inc Recent Development
Table 135. Motif Bio Plc Company Details
Table 136. Motif Bio Plc Business Overview
Table 137. Motif Bio Plc Product
Table 138. Motif Bio Plc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 139. Motif Bio Plc Recent Development
Table 140. Nabriva Therapeutics AG Company Details
Table 141. Nabriva Therapeutics AG Business Overview
Table 142. Nabriva Therapeutics AG Product
Table 143. Nabriva Therapeutics AG Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 144. Nabriva Therapeutics AG Recent Development
Table 145. Polyphor Ltd Company Details
Table 146. Polyphor Ltd Business Overview
Table 147. Polyphor Ltd Product
Table 148. Polyphor Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 149. Polyphor Ltd Recent Development
Table 150. Shionogi & Co Ltd Company Details
Table 151. Shionogi & Co Ltd Business Overview
Table 152. Shionogi & Co Ltd Product
Table 153. Shionogi & Co Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 154. Shionogi & Co Ltd Recent Development
Table 155. Tetraphase Pharmaceuticals Inc Company Details
Table 156. Tetraphase Pharmaceuticals Inc Business Overview
Table 157. Tetraphase Pharmaceuticals Inc Product
Table 158. Tetraphase Pharmaceuticals Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 159. Tetraphase Pharmaceuticals Inc Recent Development
Table 160. The Medicines Company Company Details
Table 161. The Medicines Company Business Overview
Table 162. The Medicines Company Product
Table 163. The Medicines Company Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 164. The Medicines Company Recent Development
Table 165. Theravance Biopharma Inc Company Details
Table 166. Theravance Biopharma Inc Business Overview
Table 167. Theravance Biopharma Inc Product
Table 168. Theravance Biopharma Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 169. Theravance Biopharma Inc Recent Development
Table 170. Wockhardt Ltd Company Details
Table 171. Wockhardt Ltd Business Overview
Table 172. Wockhardt Ltd Product
Table 173. Wockhardt Ltd Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 174. Wockhardt Ltd Recent Development
Table 175. Zavante Therapeutics Inc Company Details
Table 176. Zavante Therapeutics Inc Business Overview
Table 177. Zavante Therapeutics Inc Product
Table 178. Zavante Therapeutics Inc Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics Business (2015-2020) (Million US$)
Table 179. Zavante Therapeutics Inc Recent Development
Table 180. Research Programs/Design for This Report
Table 181. Key Data Information from Secondary Sources
Table 182. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Prevention Features
Figure 3. Physiotherapy Features
Figure 4. Immunity Therapy Features
Figure 5. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Ambulatory Surgical Center Case Studies
Figure 8. Diagnostic Centers Case Studies
Figure 9. Ventilator Associated Pneumonia (VAP) Therapeutics Report Years Considered
Figure 10. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions: 2020 VS 2026
Figure 12. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Ventilator Associated Pneumonia (VAP) Therapeutics Market Share by Players in 2019
Figure 15. Global Top Ventilator Associated Pneumonia (VAP) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ventilator Associated Pneumonia (VAP) Therapeutics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Ventilator Associated Pneumonia (VAP) Therapeutics Revenue in 2019
Figure 17. North America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Ventilator Associated Pneumonia (VAP) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed

---